Compare TR & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TR | FOLD |
|---|---|---|
| Founded | 1896 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 4.4B |
| IPO Year | N/A | 2007 |
| Metric | TR | FOLD |
|---|---|---|
| Price | $36.37 | $14.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $27.56 |
| AVG Volume (30 Days) | 125.1K | ★ 20.1M |
| Earning Date | 02-27-2026 | 02-18-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | ★ 0.79 | N/A |
| EPS | ★ 1.28 | N/A |
| Revenue | ★ $729,620,000.00 | $598,704,000.00 |
| Revenue This Year | N/A | $21.49 |
| Revenue Next Year | N/A | $18.42 |
| P/E Ratio | $27.90 | ★ N/A |
| Revenue Growth | 0.34 | ★ 21.28 |
| 52 Week Low | $28.67 | $5.51 |
| 52 Week High | $44.27 | $14.36 |
| Indicator | TR | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 43.64 | 89.90 |
| Support Level | $34.93 | $14.21 |
| Resistance Level | $38.17 | $14.35 |
| Average True Range (ATR) | 0.86 | 0.08 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 47.37 | 97.72 |
Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.